Rate My Professor Camille Esneau

Dr. Camille Esneau serves as a Postdoctoral Researcher and Casual Academic within the Bartlett Team at the School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Australia. She obtained her Doctor of Philosophy from the University of Newcastle, specializing in Immunology and Microbiology, and earlier degrees—a Bachelor of Science and Master of Science—from Versailles Saint-Quentin-en-Yvelines University in France. In her current role, affiliated with the Hunter Medical Research Institute, Esneau collaborates with Associate Professor Nathan Bartlett and international partners to investigate respiratory virus diversity and host-pathogen interactions. Her work emphasizes how viral variations contribute to severe respiratory diseases, with the goal of developing targeted antiviral therapies. Additionally, she holds an adjunct Associate Lecturer position at the Kirby Institute, University of New South Wales, Sydney, stemming from collaborative research efforts.

Esneau's research portfolio, centered on virology (50%), respiratory diseases (20%), and innate immunity (30%), includes extensive use of advanced models such as air-liquid interface differentiated human airway epithelial cells to study viruses like rhinoviruses, SARS-CoV-2, and respiratory syncytial virus (RSV). Notable publications feature book chapters "Rhinovirus diversity and virulence factors" (2019) and "Rhinovirus structure, replication, and classification" (2019), alongside peer-reviewed articles such as "The Pandemic REspiratory Virus Epidemiological SurveillaNce Trial - A self-swab surveillance system for respiratory viruses nested within FluTracking" (Journal of Infectious Diseases, 2025), "Opportunities for rhinovirus-targeted RNA therapeutics: A narrative review" (CMI Communications, 2025), "Understanding Rhinovirus Circulation and Impact on Illness" (Viruses, 2022), "A persistent neutrophil-associated immune signature characterizes post–COVID-19 pulmonary sequelae" (Science Translational Medicine, 2022), "Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells" (American Journal of Physiology-Lung Cellular and Molecular Physiology, 2020), and "RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription" (PLoS Pathogens, 2018).